Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2025-02-18 Sale | 2025-02-20 5:12 pm | Neumora Therapeutics Inc. | NMRA | Lenz Robert A. Head of R&D | 5,614 | $1.6714 | $9,383 | 309,092 (Direct) | View |
| 2024-10-09 Sale | 2024-10-11 4:10 pm | Neumora Therapeutics Inc. | NMRA | Lenz Robert A. Head of R&D | 13,823 | $15.06 | $208,110 | 314,706 (Direct) | View |
| 2024-09-17 Sale | 2024-09-19 4:35 pm | Neumora Therapeutics Inc. | NMRA | Lenz Robert A. Head of R&D | 41,464 | $11.89 | $492,827 | 328,529 (Direct) | View |
| 2024-09-12 Sale | 2024-09-16 4:05 pm | Neumora Therapeutics Inc. | NMRA | Lenz Robert A. Head of R&D | 32,948 | $11.43 | $376,665 | 369,993 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
Ownership | 2026-03-18 9:25 pm | N/A 2035-08-22 | NovaBridge Biosciences | NBP | Lenz Robert A. Director | 0 | $0 | 41,590 (Direct) | View |
| 2026-03-06 Option Award | 2026-03-10 4:19 pm | N/A 2036-03-05 | LB PHARMACEUTICALS INC | LBRX | Lenz Robert A. Director | 20,000 | $0 | 20,000 (Direct) | View |
| 2025-02-13 Option Award | 2025-02-18 4:30 pm | N/A 2033-09-14 | Neumora Therapeutics Inc. | NMRA | Lenz Robert A. Head of R&D | 602,934 | $0 | 602,934 (Direct) | View |
| 2024-02-14 Option Award | 2024-02-16 4:13 pm | N/A 2034-02-13 | Neumora Therapeutics Inc. | NMRA | Lenz Robert A. Head of R&D | 150,000 | $0 | 502,941 (Direct) | View |
| 2023-09-14 Option Award | 2023-09-18 5:58 pm | N/A 2033-09-13 | Neumora Therapeutics Inc. | NMRA | Lenz Robert A. Head of R&D | 855,875 | $0 | 855,875 (Direct) | View |